JPWO2020081848A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020081848A5
JPWO2020081848A5 JP2021520556A JP2021520556A JPWO2020081848A5 JP WO2020081848 A5 JPWO2020081848 A5 JP WO2020081848A5 JP 2021520556 A JP2021520556 A JP 2021520556A JP 2021520556 A JP2021520556 A JP 2021520556A JP WO2020081848 A5 JPWO2020081848 A5 JP WO2020081848A5
Authority
JP
Japan
Prior art keywords
pyrido
thio
pyrazin
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520556A
Other languages
English (en)
Japanese (ja)
Other versions
JP7449282B2 (ja
JP2022504936A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056786 external-priority patent/WO2020081848A1/en
Publication of JP2022504936A publication Critical patent/JP2022504936A/ja
Publication of JPWO2020081848A5 publication Critical patent/JPWO2020081848A5/ja
Application granted granted Critical
Publication of JP7449282B2 publication Critical patent/JP7449282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520556A 2018-10-17 2019-10-17 タンパク質チロシンホスファターゼ阻害薬 Active JP7449282B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862746952P 2018-10-17 2018-10-17
US62/746,952 2018-10-17
US201962916119P 2019-10-16 2019-10-16
US62/916,119 2019-10-16
PCT/US2019/056786 WO2020081848A1 (en) 2018-10-17 2019-10-17 Protein tyrosine phosphatase inhibitors

Publications (3)

Publication Number Publication Date
JP2022504936A JP2022504936A (ja) 2022-01-13
JPWO2020081848A5 true JPWO2020081848A5 (zh) 2022-10-07
JP7449282B2 JP7449282B2 (ja) 2024-03-13

Family

ID=68536896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520556A Active JP7449282B2 (ja) 2018-10-17 2019-10-17 タンパク質チロシンホスファターゼ阻害薬

Country Status (27)

Country Link
US (1) US20210380582A1 (zh)
EP (1) EP3867238B1 (zh)
JP (1) JP7449282B2 (zh)
KR (1) KR102649419B1 (zh)
CN (1) CN114341124A (zh)
AU (1) AU2019359885B2 (zh)
BR (1) BR112021005733A2 (zh)
CA (1) CA3116561C (zh)
CL (1) CL2021000972A1 (zh)
CO (1) CO2021004966A2 (zh)
CR (1) CR20210189A (zh)
CU (1) CU20210029A7 (zh)
CY (1) CY1126122T1 (zh)
DO (1) DOP2021000070A (zh)
EC (1) ECSP21027049A (zh)
ES (1) ES2947464T3 (zh)
HU (1) HUE062404T2 (zh)
IL (1) IL282179B1 (zh)
MA (1) MA53921A (zh)
MX (1) MX2021004410A (zh)
NI (1) NI202100027A (zh)
PE (1) PE20211465A1 (zh)
PH (1) PH12021550674A1 (zh)
PL (1) PL3867238T3 (zh)
SG (1) SG11202102985YA (zh)
WO (1) WO2020081848A1 (zh)
ZA (1) ZA202101960B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3630770A1 (en) 2017-05-26 2020-04-08 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
TW202003471A (zh) 2018-03-21 2020-01-16 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
EP3947367A1 (en) 2019-04-02 2022-02-09 Array Biopharma, Inc. Protein tyrosine phosphatase inhibitors
MX2022003454A (es) 2019-09-24 2022-04-19 Relay Therapeutics Inc Inhibidores de fosfatasa shp2 y metodos para su fabricacion y uso.
JP2023500328A (ja) 2019-11-08 2023-01-05 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN115340561A (zh) * 2021-05-14 2022-11-15 药雅科技(上海)有限公司 Shp2磷酸酶稠环类抑制剂的制备及其应用
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技(上海)有限公司 Shp2磷酸酶抑制劑的製備及其應用
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
IL309984A (en) 2021-07-09 2024-03-01 Kanaph Therapeutics Inc SHP2 inhibitor and use thereof
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202346305A (zh) * 2022-01-05 2023-12-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN114621186A (zh) * 2022-05-12 2022-06-14 上海维申医药有限公司 作为ras信号通路调控剂的杂环化合物
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek抑制劑及其用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2621470A1 (en) * 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
EP2475666A2 (en) * 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
CN103153062B (zh) * 2010-05-24 2015-07-15 因特利凯有限责任公司 杂环化合物及其用途
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2016203406A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
BR112018075663A2 (pt) 2016-06-14 2019-04-09 Novartis Ag compostos e composições para a inibição da atividade de shp2
IL264186B1 (en) 2016-07-12 2024-04-01 Revolution Medicines Inc 2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric SHP2 inhibitors
EP3515916B1 (en) * 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW201819386A (zh) * 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3571189B1 (en) 2017-01-23 2023-03-29 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
KR102665763B1 (ko) * 2017-01-23 2024-05-10 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 이환 화합물
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ,インコーポレイテッド がんを治療するためのshp2阻害剤組成物および方法

Similar Documents

Publication Publication Date Title
JPWO2020081848A5 (zh)
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
EP3867238B1 (en) Protein tyrosine phosphatase inhibitors
JP6631616B2 (ja) CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
AU2013287176C1 (en) Substituted tricyclic compounds as FGFR inhibitors
RU2020133727A (ru) Ингибиторы shp2 и их применение
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2015521600A5 (zh)
JP2020522570A5 (zh)
JP2022543689A (ja) Shp2阻害剤
JPWO2019191092A5 (zh)
JP2013519707A5 (zh)
HRP20230120T1 (hr) Inhibitori bcl6
TW202317566A (zh) 雜環化合物及使用方法
WO2022232332A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
WO2023069959A1 (en) Covalent egfr inhibitors and methods of use thereof
JPWO2019197842A5 (zh)
JPWO2019233941A5 (zh)
JPWO2020207991A5 (zh)
RU2023134860A (ru) Ингибиторы мутации her2
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
WO2024086809A1 (en) Methods for treating cancer
CN117897159A (zh) 杂环化合物及使用方法
HUE025203T2 (en) CDK4 / 6 inhibitor pyrrolopyrimidine compounds